CD8A and autoimmune hepatitis: Treatment with glucocorticoids has been found to attenuate hepatic inflammation by directly inhibiting the expansion of these CD103+CD8+TRM cells, indicating a potential therapeutic avenue for managing autoimmune liver diseases [182].